Press Journals

Peanut Allergy Therapeutics Pipeline Witnessing Significant Growth due to Rise in the Number of Patents Approvals

March 2018

Peanut allergy therapeutics currently exhibits a proliferating pipeline with 19 drug candidates, P&S Market Research

Browse report overview with detailed TOC on "Peanut Allergy Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.psmarketresearch.com/market-analysis/peanut-allergy-therapeutics-pipeline-analysis

Peanut Allergy Therapeutics Pipeline in 2018

Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately 19 drug candidates in different stages of development.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of peanut allergy are being developed to be administered by the oral route which is convenient to take, and has been considered as non-invasive, and is often a safer route that requires no special training to be given to the patients.

Peanut Allergy Therapeutics Pipeline growth characterized by Various Technological Advancements

It has been observed that most of the companies are developing drug candidates by using advanced technologies and the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, BioLingus Inc. is utilizing its technology, BioLingus technology, which is a micro-encapsulation process, that delivers macro molecules such as peptides and proteins and is particularly effective for sublingual immunotherapy. With this technology, it has been observed in the Pre-Clinical models that sublingual IL-2 is found efficacious in 500th times lower amount than the investigational sublingual IL-2 therapy for the treatment of peanut allergy.

Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.

Peanut Allergy Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company